Showing 1151-1160 of 1616 results for "".
- Early Data Find AstraZeneca’s COVID-19 Vaccine Effective Against Fast-Spreading UK Strainhttps://modernod.com/news/early-data-find-astrazenecas-covid-19-vaccine-effective-against-fast-spreading-uk-strain/2478839/A preliminary analysis suggests that AstraZeneca’s AZD1222 vaccine is effective against COVID-19 caused by the highly-transmissible UK variant, according to a statement Friday by its partners at the University of Oxford. The findings, which are not peer-reviewed and were released as a prepr
- Early Phase 3 Data Show Pfizer, BioNTech’s COVID-19 Vaccine Over 90% Effectivehttps://modernod.com/news/early-phase-3-data-show-pfizer-biontechs-covid-19-vaccine-over-90-effective/2478507/Results from the first interim analysis of a phase 3 study of Pfizer and BioNTech’s BNT162b2 showed that the experimental mRNA-based vaccine candidate was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced M
- CureVac to Move COVID-19 Vaccine Into Late-Stage Testing on Positive Early Datahttps://modernod.com/news/curevac-to-move-covid-19-vaccine-into-late-stage-testing-on-positive-early-data/2478489/CureVac reported interim phase 1 study data on Monday showing that its experimental COVID-19 vaccine triggered strong binding and neutralizing antibody responses, and also gave a “first indication” that T-cells had been activated in a cohort of healthy adult volunteers. The company sa
- Early Data Show Regeneron’s Antibody Cocktail Cuts Viral Load, Eases COVID-19 Symptomshttps://modernod.com/news/early-data-show-regenerons-antibody-cocktail-cuts-viral-load-eases-covid-19-symptoms/2478347/Regeneron Pharmaceuticals said Tuesday that adding REGN-COV2 to standard-of-care reduced viral load as well as the time to symptom alleviation in non-hospitalized patients with COVID-19. The company noted that first data from an ongoing adaptive phase 1/2/3 trial of its investigational dual antib
- J&J’s COVID-19 Vaccine “Highly Immunogenic” in Early-Stage Testinghttps://modernod.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/Interim phase 1/2a study results for Johnson & Johnson’s experimental COVID-19 vaccine JNJ-78436735 have been published online on the preprint server medRxiv, with researchers saying that a single dose was “well tolerated and highly immunogenic,” and that the findings warran
- Novavax Reports Positive Early Results for Experimental COVID-19 Vaccine NVX-CoV2373https://modernod.com/news/novavax-reports-positive-early-results-for-experimental-covid-19-vaccine-nvx-cov2373/2478122/Novavax announced preliminary data from a phase 1/2 study indicating that its recombinant coronavirus vaccine candidate NVX-CoV2373 triggered immune responses in healthy adults and was generally well-tolerated. According to findings in a paper, Novavax submitted to the preprint server medRxiv, th
- American Academy of Ophthalmology to Launch its First Open Access Journal in Early 2021https://modernod.com/news/american-academy-of-ophthalmology-to-launch-its-first-open-access-journal-in-early-2021/2477962/The American Academy of Ophthalmology announced plans to expand the Ophthalmology family of journals to include Ophthalmology Science, an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory-based work, ophthalmology
- Early Data Show Moderna’s COVID-19 Vaccine Generates Immune Responseshttps://modernod.com/news/first-covid-19-vaccine-tested-in-the-us-shows-promise-in-data-from-eight-people/2477791/Moderna reported positive interim data from a phase 1 study of its vaccine candidate against SARS-CoV-2, with results showing that mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants in the low- and mid-dose cohorts, reaching or exceeding levels generally seen
- Gilead Says Early Results of Coronavirus Drug Trial Show Improvement With Shorter Remdesivir Treatmenthttps://modernod.com/news/gilead-says-early-results-of-coronavirus-drug-trial-show-improvement-with-shorter-remdesivir-treatment/2477673/Gilead Sciences said Wednesday preliminary results of a coronavirus drug trial showed at least 50% of patients treated with a five-day dosage of remdesivir improved and more than half were discharged from the hospital within two weeks, according to a CNBC
- Regeneron’s Novel COVID-19 Antibody Program Has Potential to Enter Human Clinical Studies by Early Summerhttps://modernod.com/news/regenerons-novel-covid-19-antibody-program-has-potential-to-enter-human-clinical-studies-by-early-summer/2477404/Regeneron Pharmaceuticals announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated